Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
31,889
archived clinical trials in
Blood Cancer

Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
High Risk B-Precursor Acute Lymphoblastic Leukemia
Status: Enrolling
Updated:  7/10/2015
Primary Children's Medical Center
mi
from
Salt Lake City, UT
Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
High Risk B-Precursor Acute Lymphoblastic Leukemia
Status: Enrolling
Updated: 7/10/2015
Primary Children's Medical Center
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
High Risk B-Precursor Acute Lymphoblastic Leukemia
Status: Enrolling
Updated:  7/10/2015
Fletcher Allen Health Care - University Health Center Campus
mi
from
Burlington, VT
Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
High Risk B-Precursor Acute Lymphoblastic Leukemia
Status: Enrolling
Updated: 7/10/2015
Fletcher Allen Health Care - University Health Center Campus
mi
from
Burlington, VT
Click here to add this to my saved trials
Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
High Risk B-Precursor Acute Lymphoblastic Leukemia
Status: Enrolling
Updated:  7/10/2015
University of Virginia Cancer Center
mi
from
Charlottesville, VA
Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
High Risk B-Precursor Acute Lymphoblastic Leukemia
Status: Enrolling
Updated: 7/10/2015
University of Virginia Cancer Center
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
High Risk B-Precursor Acute Lymphoblastic Leukemia
Status: Enrolling
Updated:  7/10/2015
Inova Fairfax Hospital
mi
from
Falls Church, VA
Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
High Risk B-Precursor Acute Lymphoblastic Leukemia
Status: Enrolling
Updated: 7/10/2015
Inova Fairfax Hospital
mi
from
Falls Church, VA
Click here to add this to my saved trials
Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
High Risk B-Precursor Acute Lymphoblastic Leukemia
Status: Enrolling
Updated:  7/10/2015
Children's Hospital of The King's Daughters
mi
from
Norfolk, VA
Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
High Risk B-Precursor Acute Lymphoblastic Leukemia
Status: Enrolling
Updated: 7/10/2015
Children's Hospital of The King's Daughters
mi
from
Norfolk, VA
Click here to add this to my saved trials
Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
High Risk B-Precursor Acute Lymphoblastic Leukemia
Status: Enrolling
Updated:  7/10/2015
Naval Medical Center - Portsmouth
mi
from
Portsmouth, VA
Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
High Risk B-Precursor Acute Lymphoblastic Leukemia
Status: Enrolling
Updated: 7/10/2015
Naval Medical Center - Portsmouth
mi
from
Portsmouth, VA
Click here to add this to my saved trials
Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
High Risk B-Precursor Acute Lymphoblastic Leukemia
Status: Enrolling
Updated:  7/10/2015
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
High Risk B-Precursor Acute Lymphoblastic Leukemia
Status: Enrolling
Updated: 7/10/2015
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Click here to add this to my saved trials
Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
High Risk B-Precursor Acute Lymphoblastic Leukemia
Status: Enrolling
Updated:  7/10/2015
Carilion Medical Center for Children at Roanoke Community Hospital
mi
from
Roanoke, VA
Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
High Risk B-Precursor Acute Lymphoblastic Leukemia
Status: Enrolling
Updated: 7/10/2015
Carilion Medical Center for Children at Roanoke Community Hospital
mi
from
Roanoke, VA
Click here to add this to my saved trials
Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
High Risk B-Precursor Acute Lymphoblastic Leukemia
Status: Enrolling
Updated:  7/10/2015
Children's Hospital and Regional Medical Center - Seattle
mi
from
Seattle, WA
Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
High Risk B-Precursor Acute Lymphoblastic Leukemia
Status: Enrolling
Updated: 7/10/2015
Children's Hospital and Regional Medical Center - Seattle
mi
from
Seattle, WA
Click here to add this to my saved trials
Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
High Risk B-Precursor Acute Lymphoblastic Leukemia
Status: Enrolling
Updated:  7/10/2015
Deaconess Medical Center
mi
from
Spokane, WA
Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
High Risk B-Precursor Acute Lymphoblastic Leukemia
Status: Enrolling
Updated: 7/10/2015
Deaconess Medical Center
mi
from
Spokane, WA
Click here to add this to my saved trials
Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
High Risk B-Precursor Acute Lymphoblastic Leukemia
Status: Enrolling
Updated:  7/10/2015
Providence Cancer Center at Sacred Heart Medical Center
mi
from
Spokane, WA
Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
High Risk B-Precursor Acute Lymphoblastic Leukemia
Status: Enrolling
Updated: 7/10/2015
Providence Cancer Center at Sacred Heart Medical Center
mi
from
Spokane, WA
Click here to add this to my saved trials
Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
High Risk B-Precursor Acute Lymphoblastic Leukemia
Status: Enrolling
Updated:  7/10/2015
Mary Bridge Children's Hospital and Health Center - Tacoma
mi
from
Tacoma, WA
Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
High Risk B-Precursor Acute Lymphoblastic Leukemia
Status: Enrolling
Updated: 7/10/2015
Mary Bridge Children's Hospital and Health Center - Tacoma
mi
from
Tacoma, WA
Click here to add this to my saved trials
Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
High Risk B-Precursor Acute Lymphoblastic Leukemia
Status: Enrolling
Updated:  7/10/2015
Madigan Army Medical Center - Tacoma
mi
from
Tacoma, WA
Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
High Risk B-Precursor Acute Lymphoblastic Leukemia
Status: Enrolling
Updated: 7/10/2015
Madigan Army Medical Center - Tacoma
mi
from
Tacoma, WA
Click here to add this to my saved trials
Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
High Risk B-Precursor Acute Lymphoblastic Leukemia
Status: Enrolling
Updated:  7/10/2015
West Virginia University Health Sciences Center - Charleston
mi
from
Charleston, WV
Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
High Risk B-Precursor Acute Lymphoblastic Leukemia
Status: Enrolling
Updated: 7/10/2015
West Virginia University Health Sciences Center - Charleston
mi
from
Charleston, WV
Click here to add this to my saved trials
Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
High Risk B-Precursor Acute Lymphoblastic Leukemia
Status: Enrolling
Updated:  7/10/2015
Edwards Comprehensive Cancer Center at Cabell Huntington Hospital
mi
from
Huntington, WV
Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
High Risk B-Precursor Acute Lymphoblastic Leukemia
Status: Enrolling
Updated: 7/10/2015
Edwards Comprehensive Cancer Center at Cabell Huntington Hospital
mi
from
Huntington, WV
Click here to add this to my saved trials
Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
High Risk B-Precursor Acute Lymphoblastic Leukemia
Status: Enrolling
Updated:  7/10/2015
Mary Babb Randolph Cancer Center at West Virginia University Hospitals
mi
from
Morgantown, WV
Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
High Risk B-Precursor Acute Lymphoblastic Leukemia
Status: Enrolling
Updated: 7/10/2015
Mary Babb Randolph Cancer Center at West Virginia University Hospitals
mi
from
Morgantown, WV
Click here to add this to my saved trials
Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
High Risk B-Precursor Acute Lymphoblastic Leukemia
Status: Enrolling
Updated:  7/10/2015
St. Vincent Hospital Regional Cancer Center
mi
from
Green Bay, WI
Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
High Risk B-Precursor Acute Lymphoblastic Leukemia
Status: Enrolling
Updated: 7/10/2015
St. Vincent Hospital Regional Cancer Center
mi
from
Green Bay, WI
Click here to add this to my saved trials
Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
High Risk B-Precursor Acute Lymphoblastic Leukemia
Status: Enrolling
Updated:  7/10/2015
Gundersen Lutheran Center for Cancer and Blood
mi
from
La Crosse, WI
Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
High Risk B-Precursor Acute Lymphoblastic Leukemia
Status: Enrolling
Updated: 7/10/2015
Gundersen Lutheran Center for Cancer and Blood
mi
from
La Crosse, WI
Click here to add this to my saved trials
Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
High Risk B-Precursor Acute Lymphoblastic Leukemia
Status: Enrolling
Updated:  7/10/2015
University of Wisconsin Paul P. Carbone Comprehensive Cancer Center
mi
from
Madison, WI
Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
High Risk B-Precursor Acute Lymphoblastic Leukemia
Status: Enrolling
Updated: 7/10/2015
University of Wisconsin Paul P. Carbone Comprehensive Cancer Center
mi
from
Madison, WI
Click here to add this to my saved trials
Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
High Risk B-Precursor Acute Lymphoblastic Leukemia
Status: Enrolling
Updated:  7/10/2015
Marshfield Clinic - Marshfield Center
mi
from
Marshfield, WI
Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
High Risk B-Precursor Acute Lymphoblastic Leukemia
Status: Enrolling
Updated: 7/10/2015
Marshfield Clinic - Marshfield Center
mi
from
Marshfield, WI
Click here to add this to my saved trials
Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
High Risk B-Precursor Acute Lymphoblastic Leukemia
Status: Enrolling
Updated:  7/10/2015
Midwest Children's Cancer Center at Children's Hospital of Wisconsin
mi
from
Milwaukee, WI
Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
High Risk B-Precursor Acute Lymphoblastic Leukemia
Status: Enrolling
Updated: 7/10/2015
Midwest Children's Cancer Center at Children's Hospital of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
High Risk B-Precursor Acute Lymphoblastic Leukemia
Status: Enrolling
Updated:  7/10/2015
Royal Children's Hospital
mi
from
Brisbane,
Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
High Risk B-Precursor Acute Lymphoblastic Leukemia
Status: Enrolling
Updated: 7/10/2015
Royal Children's Hospital
mi
from
Brisbane,
Click here to add this to my saved trials
Continuous Versus Intermittent Dosing Regimens for Pomalidomide in Relapsed/Refractory Multiple Myeloma
Clinical and Pharmacodynamic Comparison of Continuous Versus Intermittent Dosing Regimens for Pomalidomide in Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  7/14/2015
Yale University
mi
from
New Haven, CT
Continuous Versus Intermittent Dosing Regimens for Pomalidomide in Relapsed/Refractory Multiple Myeloma
Clinical and Pharmacodynamic Comparison of Continuous Versus Intermittent Dosing Regimens for Pomalidomide in Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 7/14/2015
Yale University
mi
from
New Haven, CT
Click here to add this to my saved trials
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer
Status: Enrolling
Updated:  7/14/2015
CCOP - Scottsdale Oncology Program
mi
from
Scottsdale, AZ
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer
Status: Enrolling
Updated: 7/14/2015
CCOP - Scottsdale Oncology Program
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer
Status: Enrolling
Updated:  7/14/2015
CCOP - Carle Cancer Center
mi
from
Urbana, IL
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer
Status: Enrolling
Updated: 7/14/2015
CCOP - Carle Cancer Center
mi
from
Urbana, IL
Click here to add this to my saved trials
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer
Status: Enrolling
Updated:  7/14/2015
CCOP - Iowa Oncology Research Association
mi
from
Des Moines, IA
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer
Status: Enrolling
Updated: 7/14/2015
CCOP - Iowa Oncology Research Association
mi
from
Des Moines, IA
Click here to add this to my saved trials
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer
Status: Enrolling
Updated:  7/14/2015
Siouxland Hematology-Oncology
mi
from
Sioux City, IA
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer
Status: Enrolling
Updated: 7/14/2015
Siouxland Hematology-Oncology
mi
from
Sioux City, IA
Click here to add this to my saved trials
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer
Status: Enrolling
Updated:  7/14/2015
CCOP - Wichita
mi
from
Wichita, KA
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer
Status: Enrolling
Updated: 7/14/2015
CCOP - Wichita
mi
from
Wichita, KA
Click here to add this to my saved trials
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer
Status: Enrolling
Updated:  7/14/2015
Mayo Clinic Cancer Center
mi
from
Rochester, MN
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer
Status: Enrolling
Updated: 7/14/2015
Mayo Clinic Cancer Center
mi
from
Rochester, MN
Click here to add this to my saved trials
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer
Status: Enrolling
Updated:  7/14/2015
CCOP - Missouri Valley Cancer Consortium
mi
from
Omaha, NE
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer
Status: Enrolling
Updated: 7/14/2015
CCOP - Missouri Valley Cancer Consortium
mi
from
Omaha, NE
Click here to add this to my saved trials
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer
Status: Enrolling
Updated:  7/14/2015
Medcenter One Health System
mi
from
Bismarck, ND
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer
Status: Enrolling
Updated: 7/14/2015
Medcenter One Health System
mi
from
Bismarck, ND
Click here to add this to my saved trials
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer
Status: Enrolling
Updated:  7/14/2015
Altru Health Systems
mi
from
Grand Forks, ND
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer
Status: Enrolling
Updated: 7/14/2015
Altru Health Systems
mi
from
Grand Forks, ND
Click here to add this to my saved trials
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer
Status: Enrolling
Updated:  7/14/2015
CCOP - Toledo Community Hospital Oncology Program
mi
from
Toledo, OH
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer
Status: Enrolling
Updated: 7/14/2015
CCOP - Toledo Community Hospital Oncology Program
mi
from
Toledo, OH
Click here to add this to my saved trials
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer
Status: Enrolling
Updated:  7/14/2015
Rapid City Regional Hospital
mi
from
Rapid City, SD
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer
Status: Enrolling
Updated: 7/14/2015
Rapid City Regional Hospital
mi
from
Rapid City, SD
Click here to add this to my saved trials
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer
Status: Enrolling
Updated:  7/14/2015
CCOP - Sioux Community Cancer Consortium
mi
from
Sioux Falls, SD
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer
Status: Enrolling
Updated: 7/14/2015
CCOP - Sioux Community Cancer Consortium
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Cyclosporine in Treating Patients With Low Blood Counts Caused By Hematologic Cancer
Phase II Study of Cyclosporine in T-Cell Large Granular Lymphocytic Leukemia
Status: Enrolling
Updated:  7/14/2015
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Cyclosporine in Treating Patients With Low Blood Counts Caused By Hematologic Cancer
Phase II Study of Cyclosporine in T-Cell Large Granular Lymphocytic Leukemia
Status: Enrolling
Updated: 7/14/2015
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
A Trial of Reduced Intensity Conditioning and Transplantation of Haplotype Mismatched and KIR Class I Epitope-Mismatched Highly Purified CD34 Cells
Status: Enrolling
Updated:  7/14/2015
Moores UCSD Cancer Center
mi
from
La Jolla, CA
Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
A Trial of Reduced Intensity Conditioning and Transplantation of Haplotype Mismatched and KIR Class I Epitope-Mismatched Highly Purified CD34 Cells
Status: Enrolling
Updated: 7/14/2015
Moores UCSD Cancer Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
A Trial of Reduced Intensity Conditioning and Transplantation of Haplotype Mismatched and KIR Class I Epitope-Mismatched Highly Purified CD34 Cells
Status: Enrolling
Updated:  7/14/2015
Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
A Trial of Reduced Intensity Conditioning and Transplantation of Haplotype Mismatched and KIR Class I Epitope-Mismatched Highly Purified CD34 Cells
Status: Enrolling
Updated: 7/14/2015
Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
A Trial of Reduced Intensity Conditioning and Transplantation of Haplotype Mismatched and KIR Class I Epitope-Mismatched Highly Purified CD34 Cells
Status: Enrolling
Updated:  7/14/2015
UCSF Comprehensive Cancer Center
mi
from
San Francisco, CA
Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
A Trial of Reduced Intensity Conditioning and Transplantation of Haplotype Mismatched and KIR Class I Epitope-Mismatched Highly Purified CD34 Cells
Status: Enrolling
Updated: 7/14/2015
UCSF Comprehensive Cancer Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
A Trial of Reduced Intensity Conditioning and Transplantation of Haplotype Mismatched and KIR Class I Epitope-Mismatched Highly Purified CD34 Cells
Status: Enrolling
Updated:  7/14/2015
CCOP - Christiana Care Health Services
mi
from
Newark, DE
Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
A Trial of Reduced Intensity Conditioning and Transplantation of Haplotype Mismatched and KIR Class I Epitope-Mismatched Highly Purified CD34 Cells
Status: Enrolling
Updated: 7/14/2015
CCOP - Christiana Care Health Services
mi
from
Newark, DE
Click here to add this to my saved trials
Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
A Trial of Reduced Intensity Conditioning and Transplantation of Haplotype Mismatched and KIR Class I Epitope-Mismatched Highly Purified CD34 Cells
Status: Enrolling
Updated:  7/14/2015
Lombardi Comprehensive Cancer Center at Georgetown University Medical Center
mi
from
Washington,
Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
A Trial of Reduced Intensity Conditioning and Transplantation of Haplotype Mismatched and KIR Class I Epitope-Mismatched Highly Purified CD34 Cells
Status: Enrolling
Updated: 7/14/2015
Lombardi Comprehensive Cancer Center at Georgetown University Medical Center
mi
from
Washington,
Click here to add this to my saved trials
Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
A Trial of Reduced Intensity Conditioning and Transplantation of Haplotype Mismatched and KIR Class I Epitope-Mismatched Highly Purified CD34 Cells
Status: Enrolling
Updated:  7/14/2015
University of Chicago Cancer Research Center
mi
from
Chicago, IL
Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
A Trial of Reduced Intensity Conditioning and Transplantation of Haplotype Mismatched and KIR Class I Epitope-Mismatched Highly Purified CD34 Cells
Status: Enrolling
Updated: 7/14/2015
University of Chicago Cancer Research Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
A Trial of Reduced Intensity Conditioning and Transplantation of Haplotype Mismatched and KIR Class I Epitope-Mismatched Highly Purified CD34 Cells
Status: Enrolling
Updated:  7/14/2015
Holden Comprehensive Cancer Center at University of Iowa
mi
from
Iowa City, IA
Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
A Trial of Reduced Intensity Conditioning and Transplantation of Haplotype Mismatched and KIR Class I Epitope-Mismatched Highly Purified CD34 Cells
Status: Enrolling
Updated: 7/14/2015
Holden Comprehensive Cancer Center at University of Iowa
mi
from
Iowa City, IA
Click here to add this to my saved trials
Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
A Trial of Reduced Intensity Conditioning and Transplantation of Haplotype Mismatched and KIR Class I Epitope-Mismatched Highly Purified CD34 Cells
Status: Enrolling
Updated:  7/14/2015
Massachusetts General Hospital Cancer Center
mi
from
Boston, MA
Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
A Trial of Reduced Intensity Conditioning and Transplantation of Haplotype Mismatched and KIR Class I Epitope-Mismatched Highly Purified CD34 Cells
Status: Enrolling
Updated: 7/14/2015
Massachusetts General Hospital Cancer Center
mi
from
Boston, MA
Click here to add this to my saved trials
Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
A Trial of Reduced Intensity Conditioning and Transplantation of Haplotype Mismatched and KIR Class I Epitope-Mismatched Highly Purified CD34 Cells
Status: Enrolling
Updated:  7/14/2015
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
mi
from
Boston, MA
Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
A Trial of Reduced Intensity Conditioning and Transplantation of Haplotype Mismatched and KIR Class I Epitope-Mismatched Highly Purified CD34 Cells
Status: Enrolling
Updated: 7/14/2015
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
A Trial of Reduced Intensity Conditioning and Transplantation of Haplotype Mismatched and KIR Class I Epitope-Mismatched Highly Purified CD34 Cells
Status: Enrolling
Updated:  7/14/2015
University of Minnesota Cancer Center
mi
from
Minneapolis, MN
Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
A Trial of Reduced Intensity Conditioning and Transplantation of Haplotype Mismatched and KIR Class I Epitope-Mismatched Highly Purified CD34 Cells
Status: Enrolling
Updated: 7/14/2015
University of Minnesota Cancer Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
A Trial of Reduced Intensity Conditioning and Transplantation of Haplotype Mismatched and KIR Class I Epitope-Mismatched Highly Purified CD34 Cells
Status: Enrolling
Updated:  7/14/2015
Siteman Cancer Center at Barnes-Jewish Hospital
mi
from
Saint Louis, MO
Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
A Trial of Reduced Intensity Conditioning and Transplantation of Haplotype Mismatched and KIR Class I Epitope-Mismatched Highly Purified CD34 Cells
Status: Enrolling
Updated: 7/14/2015
Siteman Cancer Center at Barnes-Jewish Hospital
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
A Trial of Reduced Intensity Conditioning and Transplantation of Haplotype Mismatched and KIR Class I Epitope-Mismatched Highly Purified CD34 Cells
Status: Enrolling
Updated:  7/14/2015
UNMC Eppley Cancer Center at the University of Nebraska Medical Center
mi
from
Omaha, NE
Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
A Trial of Reduced Intensity Conditioning and Transplantation of Haplotype Mismatched and KIR Class I Epitope-Mismatched Highly Purified CD34 Cells
Status: Enrolling
Updated: 7/14/2015
UNMC Eppley Cancer Center at the University of Nebraska Medical Center
mi
from
Omaha, NE
Click here to add this to my saved trials
Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
A Trial of Reduced Intensity Conditioning and Transplantation of Haplotype Mismatched and KIR Class I Epitope-Mismatched Highly Purified CD34 Cells
Status: Enrolling
Updated:  7/14/2015
St. Joseph's Hospital and Medical Center
mi
from
Paterson, NJ
Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
A Trial of Reduced Intensity Conditioning and Transplantation of Haplotype Mismatched and KIR Class I Epitope-Mismatched Highly Purified CD34 Cells
Status: Enrolling
Updated: 7/14/2015
St. Joseph's Hospital and Medical Center
mi
from
Paterson, NJ
Click here to add this to my saved trials
Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
A Trial of Reduced Intensity Conditioning and Transplantation of Haplotype Mismatched and KIR Class I Epitope-Mismatched Highly Purified CD34 Cells
Status: Enrolling
Updated:  7/14/2015
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
A Trial of Reduced Intensity Conditioning and Transplantation of Haplotype Mismatched and KIR Class I Epitope-Mismatched Highly Purified CD34 Cells
Status: Enrolling
Updated: 7/14/2015
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials